Advertisement

Head and neck squamous cell carcinoma from an unknown primary site.

23:08 EDT 23rd May 2013 | BioPortfolio

Summary of "Head and neck squamous cell carcinoma from an unknown primary site."


BACKGROUND:
The purpose of this study is to present our experience treating patients with squamous cell carcinoma (SCC) from an unknown head and neck primary site and to determine whether a policy change eliminating the larynx and hypopharynx from the radiotherapy (RT) portals has impacted outcome.
METHODS:
One hundred seventy-nine patients received definitive RT with or without a neck dissection for SCC from an unknown head and neck primary site. RT was delivered to the ipsilateral neck alone or both sides of the neck and, usually, the potential mucosal primary sites. The median mucosal dose was 5670 cGy. The median neck dose was 6500 cGy. One hundred nine patients (61%) received a planned neck dissection.
RESULTS:
Mucosal control at 5 years was 92%. The mucosal control rate in patients with RT limited to the nasopharynx and oropharynx was 100%. The 5-year neck-control rates were as follows: N(1), 94%; N(2a), 98%; N(2b), 86%; N(2c), 86%; N(3), 57%; and overall, 81%. The 5-year cause-specific survival rates were as follows: N(1), 94%; N(2a), 88%; N(2b), 82%; N(2c), 71%; N(3), 48%; and overall, 73%. The 5-year overall survival rates were as follows: N(1), 50%; N(2a), 70%; N(2b), 59%; N(2c), 45%; N(3), 34%; and overall, 52%. Eleven patients (7%) developed severe complications.
CONCLUSION:
RT alone or combined with neck dissection results in a high probability of cure with a low risk of severe complications. Eliminating the larynx and hypopharynx from the RT portals did not compromise outcome and likely reduces treatment toxicity.

Affiliation

Department of Radiation Oncology, University of Florida College of Medicine, Gainesville, FL, USA.

Journal Details

This article was published in the following journal.

Name: American journal of otolaryngology
ISSN: 1532-818X
Pages:

Links

Medical and Biotech [MESH] Definitions

Granular Cell Tumor

Unusual tumor affecting any site of the body, but most often encountered in the head and neck. Considerable debate has surrounded the histogenesis of this neoplasm; however, it is considered to be a myoblastoma of, usually, a benign nature. It affects women more often than men. When it develops beneath the epidermis or mucous membrane, it can lead to proliferation of the squamous cells and mimic squamous cell carcinoma.

Carcinoma, Merkel Cell

A carcinoma arising from MERKEL CELLS located in the basal layer of the epidermis and occurring most commonly as a primary neuroendocrine carcinoma of the skin. Merkel cells are tactile cells of neuroectodermal origin and histologically show neurosecretory granules. The skin of the head and neck are a common site of Merkel cell carcinoma, occurring generally in elderly patients. (Holland et al., Cancer Medicine, 3d ed, p1245)

Carcinoma, Squamous Cell

A carcinoma derived from stratified squamous epithelium. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed)

Carcinoma, Non-small-cell Lung

A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.

Carcinoma, Adenosquamous

A mixed adenocarcinoma and squamous cell or epidermoid carcinoma.

PubMed Articles [ 24863 Associated PubMed Articles listed on BioPortfolio]

Primary intraosseous squamous cell carcinoma of the jaw: two new cases and review of the literature.

BACKGROUND: Primary intraosseous squamous cell carcinoma is very rare. We report two cases of primary intraosseous squamous cell carcinoma of the jaw, one arising from an odontogenic cyst and the othe...

p14ARF genetic polymorphisms and susceptibility to second primary malignancy in patients with index squamous cell carcinoma of the head and neck.

p14(ARF) , an alternate reading frame (ARF) product of the cyclin-dependent kinase inhibitor 2A locus, plays a critical role in crosstalk between the tumor protein 53 (p53) and retinoblastoma (Rb) pat...

Transoral laser microsurgery for the unknown primary: A role for lingual tonsillectomy.

Background. We conducted a retrospective review of patients with unknown primary head and neck cancer who underwent a transoral laser microsurgery (TLM) assisted search for an occult tumor. Methods. F...

Oral and oropharyngeal squamous cell carcinoma in young patients: The Netherlands Cancer Institute experience.

BACKGROUND: Head and neck squamous cell carcinoma (HNSCC) mainly affects patients between the fifth and seventh decade of life but is increasingly seen in young patients (

Differences in history of sexual behavior between patients with oropharyngeal squamous cell carcinoma and patients with squamous cell carcinoma at other head and neck sites.

BACKGROUND.: An emerging epidemic of human papillomavirus (HPV)-associated oropharyngeal cancer has been proposed. The purpose of this study was for us to compare the sexual behaviors of patients with...

Clinical Trials [ 6208 Associated Clinical Trials listed on BioPortfolio]

MAGE-A3/HPV 16 Vaccine for Squamous Cell Carcinoma of the Head and Neck

Squamous Cell Carcinoma of the Head and Neck (SCCHN) is a devastating illness, the treatment of which is associated with significant morbidity. This type of cancer affects 43,000 individua...

Re-irradiation With Fractionated Stereotactic Radiosurgery Plus Cetuximab in Patients With Recurrent Squamous Cell Carcinoma of the Head and Neck

The primary objectives of this study are to determine the 1-year progression-free survival (PFS) of previously irradiated patients with squamous cell carcinoma of the head and neck (SCCHN)...

Combination Chemotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck

The purpose of this study is to further test a combination chemotherapy regimen for the treatment of squamous cell carcinoma of the head and neck and to see if the addition of supportive m...

Docetaxel and S-1 in Head and Neck Squamous Cell Carcinoma (HNSCC)

To assess response rate of docetaxel and S-1 combination in metastatic or recurrent head and neck squamous cell carcinoma

A Study of ARQ 501 in Patients With Squamous Cell Carcinoma of the Head and Neck

This is a Phase 2, multi-center, open label study of ARQ 501 in patients with locally advanced, recurrent or metastatic squamous cell cancer of the head and neck (SCCHN).

Search BioPortfolio:
Advertisement
Advertisement

Latest Biotech, Pharma and Healthcare News

ASCO 2013: Boehringer Ingelheim to present highly anticipated new Phase III results for front-runner compounds afatinib* and nintedanib* in first- and second-line NSCLC treatment

The Market for Squamous Cell Carcinoma of the Head and Neck is Characterized by High Unmet Need of Treatment Options Based on Specific Tumor Biology

Navidea Biopharmaceuticals Announces the Presentation of Data at Upcoming Scientific Meetings in July

Head-to-head study of GSK’s Votrient® (pazopanib) vs sunitinib in advanced renal cell carcinoma meets primary endpoint; findings presented at ESMO 2012 Congress

ImmunoGen, Inc. Announces Preclinical Findings with its IMGN289 Product Candidate for the Treatment of EGFR-Overexpressing Cancers

Oncolytics Biotech® Inc. Announces Additional Positive REOLSYIN® Clinical Trial Data from Phase 2 Study in Squamous Cell Carcinoma of the Lung

Oncolytics Biotech® Inc. Meets Primary Overall Statistical Endpoint in U.S. Phase 2 Study of REOLYSIN® in Squamous Cell Lung Cancer


Searches Linking to this Article